<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2012-3476-998-13040</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="SV">Optimering av HIV behandling genom bio och h&#xE4;lsoinformatik i den globala hiv epidemin</narrative>
   <narrative xml:lang="EN">Optimization of HIV clinical care through bio- and healthinformatics in the global epidemic</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Behandling av humant immunbrist virus (hiv) infektion har lett till en dramatisk minskning i sjuklighet och d&#xF6;dlighet. Dock finns vissa hot mot den l&#xE5;ngsiktiga behandlingseffekten, framf&#xF6;r allt resistens-utveckling och biverkningar. Vi har tidigare utvecklat en mycket stor databas med &gt;55.000 europeiska patienter d&#xE4;r information om behandling och dess effekt finns. Genom att anv&#xE4;nda oss av bioinformatiska metoder har vi utvecklat ett system som kan v&#xE4;lja ut den b&#xE4;sta behandlingen efter en terapisvikt. Dock har nya hiv l&#xE4;kemedel tillkommit och ny kunskap om att &#xE4;ven den infekterade personens gen-upps&#xE4;ttning har betydelse f&#xF6;r vilken resistens och biverkningar som kan uppst&#xE5;. Vi kommer d&#xE4;rf&#xF6;r att utvidga kunskapen om detta genom l&#xE4;gga till nya data om virusets och den infekterade personens genupps&#xE4;ttning. Hiv behandlingen anv&#xE4;nds &#xE4;ven framg&#xE5;ngsrikt i l&#xE5;g-medel inkomst l&#xE4;nder. P.g.a knappa ekonomiska resurser kan dock inte patienterna f&#xF6;ljas med laboratoriemetoder p&#xE5; samma s&#xE4;tt som i Europa. Detta har medf&#xF6;rt att multiresistens har blivit vanligt och att smitta med resistent virus blir allt vanligare. Vi kommer d&#xE4;rf&#xF6;r att p&#xE5; basis av ett samarbete med Etiopien ta fram en ett fl&#xF6;desschema, en s.k. klinisk algoritm, med vilken vi avser att kunna identifiera de etiopiska patienter d&#xE4;r behandlingen b&#xF6;rjar svikta utan att beh&#xF6;va anv&#xE4;nda dyra laboratorie-metoder. Dessutom avser vi att utveckla v&#xE5;r bioinformatiska metod s&#xE5; att den anpassas till afrikanska f&#xF6;rh&#xE5;llanden och d&#xE4;r m&#xE5;ls&#xE4;ttningen &#xE4;r att metoden ska kunna hj&#xE4;lpa till att v&#xE4;lja den b&#xE4;sta behandlingen efter en terapisvikt utan att resistens-testning beh&#xF6;ver g&#xF6;ras. Om denna kliniska algoritm och en s&#xE5;dan bioinformatisk metod kan tas fram bed&#xF6;mmer vi att dessa kan komma vara mycket betydelsefulla i m&#xE5;ls&#xE4;ttningen att hiv behandlingen &#xE4;ven i framtiden ska vara framg&#xE5;ngsrik i alla l&#xE4;nder.</narrative>
   <narrative xml:lang="EN">The project aim at studying transmitted and acquired HIV drug resistance and to develop a clinical algorithm for identifying patients who fail antiretroviral therapy (ART) and a bioinformatics engine which will predict the best HIV drug combination to use after failure. The study is based on two large HIV cohorts; Swedish/EuResist and the Ethiopian ACM. The EuResist includes &gt;55.000 patients and the ACM 800 patients from 7 geographically distinct sites in Ethiopia. We have earlier shown that our bioinformatic approach is better than other available methods for the choice of HIV drugs after failure. We will now further develop it by introducing three new scientific aspects: resistance to new categories of HIV drugs, epitope mapping and HLA-testing, into our research. For Africa, biostatistics based on the unique Ethiopian cohort, a clinical algorithm will be developed with which patients who fail therapy can be identified without costly laboratory assays. Also, African treatment data will feed the bioinformatic engine with the aim of developing methodology which can predict the best drug combination to use without resistance testing. If the project succeeds, the algorithm and the engine will be freely available on the internet and are likely to have a major impact on clinical care and research in the global HIV epidemic.</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">University, college or other teaching institution, research institute or think-tank</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2013-01-01" type="1"></activity-date>
  <activity-date iso-date="2013-01-01" type="2"></activity-date>
  <activity-date iso-date="2015-12-31" type="3"></activity-date>
  <activity-date iso-date="2015-12-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Developing countries, unspecified</narrative>
  </recipient-region>
  <sector code="130" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Population Policies/Programmes &amp; Reproductive Health</narrative>
  </sector>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2013-01-01"></period-start>
   <period-end iso-date="2013-12-28"></period-end>
   <value currency="USD" value-date="2013-01-01">69090.4624454953</value>
  </budget>
  <budget>
   <period-start iso-date="2014-01-01"></period-start>
   <period-end iso-date="2014-12-28"></period-end>
   <value currency="USD" value-date="2014-01-01">65598.6238866456</value>
  </budget>
  <budget>
   <period-start iso-date="2015-01-01"></period-start>
   <period-end iso-date="2015-12-28"></period-end>
   <value currency="USD" value-date="2015-01-01">94907.0504075072</value>
  </budget>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">93496.1725004383</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2012-10-25"></transaction-date>
   <value currency="USD" value-date="2012-10-25">199441.5636218588</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2014-01-28"></transaction-date>
   <value currency="USD" value-date="2014-01-28">65598.6238866456</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-01-28"></transaction-date>
   <value currency="USD" value-date="2015-01-28">53385.2158542228</value>
  </transaction>
  <document-link format="APPLICATION/PDF" url="http://upload.openaid.se/document/ingen-myndighet-vald/generella-bidragsvillkor-2013.pdf">
   <title>
    <narrative xml:lang="SV">Generella bidragsvillkor 2013</narrative>
   </title>
   <category code="A04"></category>
  </document-link>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
